-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Analyzing Lisata Therapeutics (NASDAQ:LSTA) and Progyny (NASDAQ:PGNY)
Analyzing Lisata Therapeutics (NASDAQ:LSTA) and Progyny (NASDAQ:PGNY)
Progyny (NASDAQ:PGNY – Get Rating) and Lisata Therapeutics (NASDAQ:LSTA – Get Rating) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.
Profitability
This table compares Progyny and Lisata Therapeutics' net margins, return on equity and return on assets.
Get Progyny alerts:Net Margins | Return on Equity | Return on Assets | |
Progyny | 6.00% | 14.14% | 9.62% |
Lisata Therapeutics | N/A | -29.53% | -27.96% |
Earnings & Valuation
This table compares Progyny and Lisata Therapeutics' revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Progyny | $500.62 million | 5.71 | $65.77 million | $0.42 | 73.33 |
Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.20 |
Institutional and Insider Ownership
86.1% of Progyny shares are owned by institutional investors. Comparatively, 6.0% of Lisata Therapeutics shares are owned by institutional investors. 14.0% of Progyny shares are owned by insiders. Comparatively, 2.2% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations for Progyny and Lisata Therapeutics, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Progyny | 0 | 0 | 3 | 0 | 3.00 |
Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Progyny presently has a consensus target price of $54.33, suggesting a potential upside of 76.41%. Lisata Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 500.00%. Given Lisata Therapeutics' higher probable upside, analysts clearly believe Lisata Therapeutics is more favorable than Progyny.
Volatility & Risk
Progyny has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.
Summary
Progyny beats Lisata Therapeutics on 11 of the 12 factors compared between the two stocks.
About Progyny
(Get Rating)
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
About Lisata Therapeutics
(Get Rating)
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
Progyny (NASDAQ:PGNY – Get Rating) and Lisata Therapeutics (NASDAQ:LSTA – Get Rating) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.
纳斯达克:PGNY-GET评级)和利萨塔治疗公司(纳斯达克:LSTA-GET评级)都是医疗公司,但哪一项投资更具优势?我们将根据这两家公司的收益、风险、机构所有权、股息、盈利能力、估值和分析师的建议来比较它们的实力。
Profitability
盈利能力
This table compares Progyny and Lisata Therapeutics' net margins, return on equity and return on assets.
此表比较了普罗吉尼和利萨塔治疗公司的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Progyny | 6.00% | 14.14% | 9.62% |
Lisata Therapeutics | N/A | -29.53% | -27.96% |
净利润率 | 股本回报率 | 资产回报率 | |
孕期 | 6.00% | 14.14% | 9.62% |
利萨塔治疗公司 | 不适用 | -29.53% | -27.96% |
Earnings & Valuation
收益与估值
This table compares Progyny and Lisata Therapeutics' revenue, earnings per share and valuation.
下表比较了普罗吉尼和利萨塔治疗公司的收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Progyny | $500.62 million | 5.71 | $65.77 million | $0.42 | 73.33 |
Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.20 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
孕期 | 5.062亿美元 | 5.71 | 6,577万美元 | $0.42 | 73.33 |
利萨塔治疗公司 | 不适用 | 不适用 | -2,747万元 | ($12.23) | -0.20 |
Institutional and Insider Ownership
机构和内部人持股
86.1% of Progyny shares are owned by institutional investors. Comparatively, 6.0% of Lisata Therapeutics shares are owned by institutional investors. 14.0% of Progyny shares are owned by insiders. Comparatively, 2.2% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Progyny 86.1%的股份由机构投资者持有。相比之下,李萨塔治疗公司6.0%的股份由机构投资者持有。Progyny 14.0%的股份由内部人士持有。相比之下,李萨塔治疗公司2.2%的股份由内部人士持有。强大的机构持股表明,大型基金管理公司、对冲基金和捐赠基金相信,一只股票有望实现长期增长。
Analyst Ratings
分析师评级
This is a summary of recent recommendations for Progyny and Lisata Therapeutics, as reported by MarketBeat.com.
这是MarketBeat.com报道的对Progyny和Lisata治疗公司最近建议的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Progyny | 0 | 0 | 3 | 0 | 3.00 |
Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
孕期 | 0 | 0 | 3 | 0 | 3.00 |
利萨塔治疗公司 | 0 | 0 | 2 | 0 | 3.00 |
Progyny presently has a consensus target price of $54.33, suggesting a potential upside of 76.41%. Lisata Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 500.00%. Given Lisata Therapeutics' higher probable upside, analysts clearly believe Lisata Therapeutics is more favorable than Progyny.
Progyny目前的共识目标价为54.33美元,暗示潜在上行76.41%。利萨塔治疗公司的共识目标价为15美元,暗示潜在上涨500.00%。鉴于李萨塔治疗公司更有可能上行,分析人士显然认为利萨塔治疗公司比Progyny更有利。
Volatility & Risk
波动性与风险
Progyny has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.
Progyny的贝塔系数为1.55,这表明其股价的波动性比标准普尔500指数高55%。相比之下,李萨塔治疗公司的贝塔指数为0.97,这表明其股价的波动性比标准普尔500指数低3%。
Summary
摘要
Progyny beats Lisata Therapeutics on 11 of the 12 factors compared between the two stocks.
在两只股票之间的12个因素中,Progyny在11个因素上击败了李萨塔治疗公司。
About Progyny
关于Progyny
(Get Rating)
(获取评级)
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Progyny,Inc.是一家福利管理公司,专门为美国雇主提供生育和家庭建设福利解决方案。其生育福利解决方案包括差异化福利计划设计、个性化礼宾式会员支持服务和有选择的生育专家网络。该公司还提供Progyny Rx,这是一种综合药房福利解决方案,为其成员提供治疗期间所需的药物。此外,它还为雇主提供代孕和领养补偿计划。该公司前身为Auxogyn,Inc.,并于2015年更名为Progyny,Inc.。Progyny,Inc.成立于2008年,总部设在纽约。
About Lisata Therapeutics
关于李萨塔治疗公司
(Get Rating)
(获取评级)
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
利萨塔治疗公司是一家临床阶段的生物制药公司,专注于开发细胞疗法并将其商业化,以逆转疾病和/或促进受损组织的再生。它的候选产品包括接受Sakigake指定的HONEDRA,用于治疗严重肢体缺血的第二阶段临床试验;XOWNA,用于治疗冠状动脉微血管功能障碍的第二阶段临床试验;以及CLBS201,一种用于治疗慢性肾脏疾病透析前患者的CD34+细胞疗法。该公司前身为NeoStem,Inc.,并于2015年6月更名为Caladrius Biosciences,Inc.。该公司前身为Caladrius Biosciences,Inc.,并于2022年9月15日更名为李萨塔治疗公司。利萨塔治疗公司成立于1980年,总部设在新泽西州的巴斯金里奇。
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
接受Progyny Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Progyny和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧